{"title":"Intuitive Human-Artificial Intelligence Theranostic Complementarity.","authors":"J Harvey Turner","doi":"10.1089/cbr.2025.0021","DOIUrl":null,"url":null,"abstract":"<p><p>Deep learning artificial intelligence (AI) algorithms are poised to subsume diagnostic imaging specialists in radiology and nuclear medicine, where radiomics can consistently outperform human analysis and reporting capability, and do it faster, with greater accuracy and reliability. However, claims made for generative AI in respect of decision-making in the clinical practice of theranostic nuclear medicine are highly contentious. Statistical computer algorithms cannot emulate human emotion, reason, instinct, intuition, or empathy. AI simulates intelligence without possessing it. AI has no understanding of the meaning of its outputs. The unique statistical probability attributes of large language models of AI must be complemented by the innate human intuitive capabilities of nuclear physicians who accept the responsibility and accountability for direct clinical care of each individual patient referred for theranostic management of specified cancers. Complementarity envisions synergistic engagement with AI radiomics, genomics, radiobiology, dosimetry, and data collation from multidimensional sources, including the electronic medical record, to enable the nuclear physician to spend informed face time with their patient. Together with physician discernment, application of the technical insights from AI will facilitate optimal formulation of a personalized precision theranostic strategy for empathic, efficacious, targeted treatment of the patient with cancer in accordance with their wishes.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"153-160"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2025.0021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Deep learning artificial intelligence (AI) algorithms are poised to subsume diagnostic imaging specialists in radiology and nuclear medicine, where radiomics can consistently outperform human analysis and reporting capability, and do it faster, with greater accuracy and reliability. However, claims made for generative AI in respect of decision-making in the clinical practice of theranostic nuclear medicine are highly contentious. Statistical computer algorithms cannot emulate human emotion, reason, instinct, intuition, or empathy. AI simulates intelligence without possessing it. AI has no understanding of the meaning of its outputs. The unique statistical probability attributes of large language models of AI must be complemented by the innate human intuitive capabilities of nuclear physicians who accept the responsibility and accountability for direct clinical care of each individual patient referred for theranostic management of specified cancers. Complementarity envisions synergistic engagement with AI radiomics, genomics, radiobiology, dosimetry, and data collation from multidimensional sources, including the electronic medical record, to enable the nuclear physician to spend informed face time with their patient. Together with physician discernment, application of the technical insights from AI will facilitate optimal formulation of a personalized precision theranostic strategy for empathic, efficacious, targeted treatment of the patient with cancer in accordance with their wishes.
期刊介绍:
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.
The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.